344 related articles for article (PubMed ID: 23852369)
41. Synthetic lethal interaction between PI3K/Akt/mTOR and Ras/MEK/ERK pathway inhibition in rhabdomyosarcoma.
Guenther MK; Graab U; Fulda S
Cancer Lett; 2013 Sep; 337(2):200-9. PubMed ID: 23684925
[TBL] [Abstract][Full Text] [Related]
42. The power of chemotherapeutic engineering: arresting cell cycle and suppressing senescence to protect from mitotic inhibitors.
Blagosklonny MV
Cell Cycle; 2011 Jul; 10(14):2295-8. PubMed ID: 21715978
[TBL] [Abstract][Full Text] [Related]
43. Multifaceted regulation of cell cycle progression by estrogen: regulation of Cdk inhibitors and Cdc25A independent of cyclin D1-Cdk4 function.
Foster JS; Henley DC; Bukovsky A; Seth P; Wimalasena J
Mol Cell Biol; 2001 Feb; 21(3):794-810. PubMed ID: 11154267
[TBL] [Abstract][Full Text] [Related]
44. Induction of Therapeutic Senescence in Vemurafenib-Resistant Melanoma by Extended Inhibition of CDK4/6.
Yoshida A; Lee EK; Diehl JA
Cancer Res; 2016 May; 76(10):2990-3002. PubMed ID: 26988987
[TBL] [Abstract][Full Text] [Related]
45. Interaction between mTOR pathway inhibition and autophagy induction attenuates adriamycin-induced vascular smooth muscle cell senescence through decreased expressions of p53/p21/p16.
Sung JY; Lee KY; Kim JR; Choi HC
Exp Gerontol; 2018 Aug; 109():51-58. PubMed ID: 28797827
[TBL] [Abstract][Full Text] [Related]
46. Synergistic anti-tumor effects of RAD001 with MEK inhibitors in neuroendocrine tumors: a potential mechanism of therapeutic limitation of mTOR inhibitor.
Iida S; Miki Y; Ono K; Akahira J; Nakamura Y; Suzuki T; Sasano H
Mol Cell Endocrinol; 2012 Mar; 350(1):99-106. PubMed ID: 22178087
[TBL] [Abstract][Full Text] [Related]
47. GSK3 is required for rapalogs to induce degradation of some oncogenic proteins and to suppress cancer cell growth.
Koo J; Wang X; Owonikoko TK; Ramalingam SS; Khuri FR; Sun SY
Oncotarget; 2015 Apr; 6(11):8974-87. PubMed ID: 25797247
[TBL] [Abstract][Full Text] [Related]
48. Uncoupling between phenotypic senescence and cell cycle arrest in aging p21-deficient fibroblasts.
Dulić V; Beney GE; Frebourg G; Drullinger LF; Stein GH
Mol Cell Biol; 2000 Sep; 20(18):6741-54. PubMed ID: 10958672
[TBL] [Abstract][Full Text] [Related]
49. Role of glycogen synthase kinase 3beta in rapamycin-mediated cell cycle regulation and chemosensitivity.
Dong J; Peng J; Zhang H; Mondesire WH; Jian W; Mills GB; Hung MC; Meric-Bernstam F
Cancer Res; 2005 Mar; 65(5):1961-72. PubMed ID: 15753396
[TBL] [Abstract][Full Text] [Related]
50. A novel tankyrase inhibitor, MSC2504877, enhances the effects of clinical CDK4/6 inhibitors.
Menon M; Elliott R; Bowers L; Balan N; Rafiq R; Costa-Cabral S; Munkonge F; Trinidade I; Porter R; Campbell AD; Johnson ER; Esdar C; Buchstaller HP; Leuthner B; Rohdich F; Schneider R; Sansom O; Wienke D; Ashworth A; Lord CJ
Sci Rep; 2019 Jan; 9(1):201. PubMed ID: 30655555
[TBL] [Abstract][Full Text] [Related]
51. CDK inhibitors (p16/p19/p21) induce senescence and autophagy in cancer-associated fibroblasts, "fueling" tumor growth via paracrine interactions, without an increase in neo-angiogenesis.
Capparelli C; Chiavarina B; Whitaker-Menezes D; Pestell TG; Pestell RG; Hulit J; Andò S; Howell A; Martinez-Outschoorn UE; Sotgia F; Lisanti MP
Cell Cycle; 2012 Oct; 11(19):3599-610. PubMed ID: 22935696
[TBL] [Abstract][Full Text] [Related]
52. Cooperative regulation of the cell division cycle by the protein kinases RAF and AKT.
Mirza AM; Gysin S; Malek N; Nakayama K; Roberts JM; McMahon M
Mol Cell Biol; 2004 Dec; 24(24):10868-81. PubMed ID: 15572689
[TBL] [Abstract][Full Text] [Related]
53. p21(Waf1) is required for cellular senescence but not for cell cycle arrest induced by the HDAC inhibitor sodium butyrate.
Romanov VS; Abramova MV; Svetlikova SB; Bykova TV; Zubova SG; Aksenov ND; Fornace AJ; Pospelova TV; Pospelov VA
Cell Cycle; 2010 Oct; 9(19):3945-55. PubMed ID: 20935470
[TBL] [Abstract][Full Text] [Related]
54. ErbB2/neu kinase modulates cellular p27(Kip1) and cyclin D1 through multiple signaling pathways.
Lenferink AE; Busse D; Flanagan WM; Yakes FM; Arteaga CL
Cancer Res; 2001 Sep; 61(17):6583-91. PubMed ID: 11522658
[TBL] [Abstract][Full Text] [Related]
55. Cyclin D1 degradation and p21 induction contribute to growth inhibition of colorectal cancer cells induced by epigallocatechin-3-gallate.
Zhang X; Min KW; Wimalasena J; Baek SJ
J Cancer Res Clin Oncol; 2012 Dec; 138(12):2051-60. PubMed ID: 22814742
[TBL] [Abstract][Full Text] [Related]
56. PDGF-induced vascular smooth muscle cell proliferation is associated with dysregulation of insulin receptor substrates.
Zhao Y; Biswas SK; McNulty PH; Kozak M; Jun JY; Segar L
Am J Physiol Cell Physiol; 2011 Jun; 300(6):C1375-85. PubMed ID: 21325637
[TBL] [Abstract][Full Text] [Related]
57. [Role of MEK/ERK pathway in the regulation of HDACI-induced senescence of transformed rat embryo fibroblasts].
Kochetkova EIu; Bykova TV; Zubova SG; Pospelova TV
Tsitologiia; 2014; 56(8):581-90. PubMed ID: 25697003
[TBL] [Abstract][Full Text] [Related]
58. Targeting cancer stem cells in glioblastoma multiforme using mTOR inhibitors and the differentiating agent all-trans retinoic acid.
Friedman MD; Jeevan DS; Tobias M; Murali R; Jhanwar-Uniyal M
Oncol Rep; 2013 Oct; 30(4):1645-50. PubMed ID: 23877261
[TBL] [Abstract][Full Text] [Related]
59. Specific Antileukemic Activity of PD0332991, a CDK4/6 Inhibitor, against Philadelphia Chromosome-Positive Lymphoid Leukemia.
Nemoto A; Saida S; Kato I; Kikuchi J; Furukawa Y; Maeda Y; Akahane K; Honna-Oshiro H; Goi K; Kagami K; Kimura S; Sato Y; Okabe S; Niwa A; Watanabe K; Nakahata T; Heike T; Sugita K; Inukai T
Mol Cancer Ther; 2016 Jan; 15(1):94-105. PubMed ID: 26637365
[TBL] [Abstract][Full Text] [Related]
60. Angiotensin II-induced transcriptional activation of the cyclin D1 gene is mediated by Egr-1 in CHO-AT(1A) cells.
Guillemot L; Levy A; Raymondjean M; Rothhut B
J Biol Chem; 2001 Oct; 276(42):39394-403. PubMed ID: 11502738
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
